Extensive molecular profiling revealed that a number of components of the IGF pathway, including IRS2 and IGFBP5, may play key roles in determining the sensitivity of cancer cells to humanized IGF1R antibody figitumumab (36). Here, IGFBP5 is linked to cancer.